ABT-199 [1257044-40-8]

Catalog number: HY-15531_100mg
Brand: MedChem Express
Packing: 100 mg
Other sizes: 5 mg
10 mM
10 mg
50 mg
200 mg
Price: € 156.60 € 174.00
Expected delivery time: 10 days
Quantity:

Product specifications for - ABT-199 [1257044-40-8]

Overview: 
Product group: Chemicals
Category: Inhibitors / activators
CAS No.: 1257044-40-8
Properties: 
Purity: >98%
Molecular Formula: C45H50ClN7O7S
Molecular weight: 868.4392
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of 4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. IC50 Value: <0.01 nM (Ki) Target: Bcl-2 selective ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: HY-15531; GDC-0199; ABT199; ABT 199; GDC0199; GDC 0199; Venetoclax
Co-targeting Aurora kinase A and Bcl-2 synergistically inhibits the viability in double-hit lymphoma cells', Ling-Zhe Kong. Translational Cancer Research (TCR). Vol 6, No 4. 2017. Read more
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.', Abed MN. J Ovarian Res. 2016 Apr 14;9(1):25. Read more
Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma', Dong Z. Br J Cancer. 2017 Jun 6;116(12):1572-1584. Read more
Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor', Wu X. Nat Cell Biol. 2017 Oct;19(10):1226-1236. Read more
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia', Reyna DE. Cancer Cell. 2017 Oct 9;32(4):490-505.e10. Read more